Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Receives undisclosed grant from Maryland-based non profit Cystic Fibrosis Foundation for a study on its drug candidate XF-73 on disease-causing bacteria MRSA.
MRSA stands for methicillin-resistant Staphylococcus aureus, a type of bacteria which caused more than 100,000 deaths worldwide in 2019, according to a 2020 paper by the University of Oxford. It is often resistant to several antibiotics. ‘The tailored research will allow us to demonstrate the potential of XF-73 in alleviating the suffering of thousands of MRSA-infected cystic fibrosis patients and is another programme derived from our proprietary XF platform,’ explains Destiny Pharma.
Cystic fibrosis is a ‘genetic disease that causes persistent lung infections and limits the ability to breathe,’ Destiny explains. Infections with MRSA are one of the reasons for lung infections, with about 25% of people with cystic fibrosis having MRSA, Destiny adds.
Last week Thursday, Destiny Pharma announced positive results that open the way for further studies with multidrug resistant strains of Pseudomonas aeruginosa and MRSA to progress the combination of XF-73 with antibacterials as potential new treatments for serious lung and diabetic foot ulcer infections.
Current stock price: 37.68 pence, down 1.5% on Tuesday
12-month change: down 70%
Copyright 2022 Alliance News Limited. All Rights Reserved.
